Biotest AG (Biotest AG) Cash Ratio : 0.31 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Biotest AG's Cash Ratio for the quarter that ended in Dec. 2023 was 0.31.

Biotest AG has a Cash Ratio of 0.31. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Biotest AG's Cash Ratio or its related term are showing as below:

BIESF' s Cash Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.84 Max: 1.82
Current: 0.31

During the past 13 years, Biotest AG's highest Cash Ratio was 1.82. The lowest was 0.11. And the median was 0.84.

BIESF's Cash Ratio is ranked worse than
87.34% of 1525 companies
in the Biotechnology industry
Industry Median: 2.9 vs BIESF: 0.31

Biotest AG Cash Ratio Historical Data

The historical data trend for Biotest AG's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Cash Ratio Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Ratio

Get a 7-Day Free Trial

0.75

0.84

1.10

1.05

0.31

Biotest AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Ratio	Get a 7-Day Free Trial															1.05	0.67	0.58	0.54	0.31

Competitive Comparison of Biotest AG's Cash Ratio

For the Biotechnology subindustry, Biotest AG's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest AG's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cash Ratio falls into.

Biotest AG Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Biotest AG's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	129.226	/	420.174
	=	0.31

Biotest AG's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	129.226	/	420.174
	=	0.31

Biotest AG (OTCPK:BIESF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.

Biotest AG Cash Ratio Related Terms

Thank you for viewing the detailed overview of Biotest AG's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Cash Ratio

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.